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Summary
Background: With the global efforts to eradicate hepatitis C virus (HCV), treatment 
during pregnancy is becoming a priority for research as this, and maternal cure should 
reduce vertical transmission. However, as information on the efficacy and safety of 
direct‐acting antivirals (DAAs) in pregnancy is generally lacking, treatment of HCV 
infection during pregnancy is not currently recommended.
Aim: To provide an overview of current knowledge regarding maternal exposure, pla‐
cental handling and safety of DAAs during pregnancy and lactation
Methods: A literature search was performed focusing on the effect of pregnancy on 
maternal exposure to DAAs, the placental handling of DAAs, the safety of DAAs for 
mother and child during pregnancy and the safety of DAAs during lactation.
Results: Exposure to all DAAs studied is likely to be altered during pregnancy, mostly 
related to pregnancy‐induced effects on drug absorption and metabolism. Although 
animal studies show that most DAAs are reported to cross the placenta and transfer 
into breast milk, most DAA combinations show a favourable safety profile. Because 
of the rapid viral decline after treatment initiation, and to avoid the critical period of 
organogenesis, treatment may be started at the end of the second trimester or early 
third trimester.
Conclusions: Treatment of HCV infection during pregnancy is realistic, as DAAs are 
highly effective and treatment duration is relatively short. There is an urgent need 
to study DAAs during pregnancy and lactation to contribute to the goal of HCV 
elimination.
This is an open access article under the terms of the Creat ive Commo ns Attri bution‐NonCo mmercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2019 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd
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1  | INTRODUC TION
In 2015, there were an estimated 71 million persons chronically 
infected with hepatitis C virus (HCV), resulting in 1.34 million 
deaths that year.1 With the global efforts of the World Health 
Organization to eradicate HCV by 2030, it is important to iden‐
tify individuals at risk and provide treatment as soon as possible 
after diagnosis.2 While the majority of infections among adults in 
many settings are linked to injection drug use, the most import‐
ant source of paediatric HCV infection is vertical transmission of 
the virus, responsible for approximately 60% of paediatric HCV 
cases globally.3,4 Among pregnant women, estimates of HCV prev‐
alence have ranged from 0.1% to 8% from different countries and 
settings.5‐8
1.1 | Vertical transmission of HCV
A large meta‐analysis performed by Benova et al reported a 5.8% 
risk of vertical transmission of HCV, resulting in 1700 HCV‐infected 
newborns in the USA yearly.9,10 In addition to high maternal HCV 
viral load, the review states that maternal HIV co‐infection in‐
creased the risk of vertical transmission of HCV to around 10%.9,11,12 
However, the majority of the co‐infected pregnant women included 
were not taking antiretroviral therapy, and a recent study suggested 
that those on antiretroviral therapy have a similar risk of transmitting 
HCV to those with HCV mono‐infection.13 The prevalence of HCV 
and HIV co‐infection among pregnant women varies across settings. 
One study in Rwanda reported that 3.9% of pregnant women with 
HCV were co‐infected with HIV.14 In a Western/Central European 
cohort of pregnant women living with HIV, 12% were co‐infected 
with HCV.14,15 In addition to high maternal HCV viral load and hav‐
ing HIV, membrane rupture for more than 6 hours before delivery 
and internal foetal monitoring (uterine or foetal scalp) have been 
reported to contribute to an increased risk of vertical HCV transmis‐
sion.16 Currently, most studies suggest that the risk of transmission 
may be reduced by elective caesarean section, particularly in the 
case of HCV/HIV co‐infection.17‐19 Based on timing of positive HCV 
RNA test results in the newborn, timing of transmission is thought 
to occur during intrauterine, peripartum and postpartum periods.20 
Transmission may be most frequent during the peripartum period 
(estimated 40%‐50%) when there is blood‐blood contact during de‐
livery. In this case, the child will be born HCV‐RNA negative, but 
detectable RNA levels are expected after the first 3 days of life. It is 
estimated that intrauterine transmission accounts for approximately 
30% of the cases, based on HCV‐RNA positivity at or shortly after 
delivery.21 The exact mechanisms by which intrauterine transmission 
occurs are not well understood, but may include trophoblast‐medi‐
ated endocytosis of HCV and/or transcytosis of viral particles.22 
Postpartum transmission via breastfeeding is rare, as the proportion 
of children acquiring HCV is similar among those who were breast‐
fed compared to those who were not.17
1.2 | Testing and consequences of HCV 
in the newborn
Although vertical transmission seems to be the most important 
source of paediatric HCV infection, a retrospective cohort study 
showed that many children of women with chronic HCV are not 
screened and therefore many paediatric HCV cases will be missed.23 
A critical reason for the low proportion of exposed infants who are 
screened is related to the delay in diagnosis, as HCV antibody testing 
can only be performed at or after 18 months of age, and the chance 
of loss to follow‐up in the intervening period is high.24 Testing for 
HCV‐RNA positivity in the newborn is generally not routinely per‐
formed, but should be recommended in infants born to HCV‐RNA 
positive mothers.25 The majority (80%) of children acquiring HCV 
through vertical transmission do not clear the infection spontane‐
ously, resulting in chronic paediatric HCV infection.26 Although 
liver injury from chronic HCV infection generally progresses slowly 
early in life, serious liver damage can occur during childhood and 
beyond.27‐29 One centre reported five children (out of 91 included 
patients, mean age: 9 years) with an accelerated course of HCV and 
early development of decompensated liver disease requiring liver 
transplantation, two of whom subsequently died.30 In addition to 
concerns about the physical health of the child with HCV, there 
may be high levels of distress in the family.31 Treatment regimens 
based on direct‐acting antivirals (DAAs) for children with chronic 
HCV ≥ 12 years of age or ≥ 35 kilograms were approved by the FDA 
in April 2017.32 Phase I and II trials of several DAA combinations for 
children aged 3‐12 years are currently ongoing [ClinicalTrials.gov: 
NCT03067129, NCT03080415, NCT03487848, NCT03022981]. 
Unfortunately, there will be no treatment available prior to the 
age of 3 in the near future as this is not requested by the European 
Medicines Agency (EMA). Therefore, treatment of children with 
vertically acquired HCV may be complicated as loss to follow‐up 
in healthcare later in life is likely to be high, as is the case in some 
settings for HIV.33,34
1.3 | Effect of HCV on pregnancy outcome
In addition to the risk of vertical HCV transmission, maternal HCV 
infection may increase the risk of adverse pregnancy outcomes. 
Recently, a protocol has been published for a study which will un‐
dertake an extensive systematic review of pregnancy outcomes 
in women with HCV; results are expected soon.35 Only a small 
proportion of available studies have sufficient power to adjust for 
potential confounding variables such as tobacco, alcohol and drug 
use. These studies report an association between maternal HCV 
infection and the risk of gestational diabetes and intrahepatic chol‐
estasis of pregnancy.36,37 In addition, an increased risk of preterm 
birth was reported and children born to women living with HCV 
were more likely to have a lower birth weight and to be small for 
gestational age.38‐41
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1.4 | Considerations for HCV treatment 
during pregnancy
Diagnosis and treatment of HCV in pregnant women is becoming a 
priority area of research as this has potential, not only to cure the 
mother, but also to prevent vertical transmission.42,43 Until recently, 
ribavirin was a cornerstone of HCV therapy. As this drug is known 
to be teratogenic and embryotoxic in all animal species studied, its 
use—and consequently all classical forms of HCV therapy—during 
pregnancy has been contra‐indicated.44 However, new, potentially 
much safer combinations of DAAs drugs are now available that are 
ribavirin free. The relative short duration of treatment (8‐12 weeks) 
and the rapid viral load decline following treatment initiation makes 
treatment and cure of women with chronic HCV late in pregnancy re‐
alistic.24,45 Testing and treatment during pregnancy seems a unique 
opportunity, as loss to follow‐up of mother and child postpartum is 
high in many low and middle income country settings, and pregnant 
women are engaged in healthcare during this period, being highly 
motivated to take actions to ensure their own health and the health 
of their unborn child.23,46,47 In 2018, the American Association for 
the Study of Liver Disease (AASLD)/Infectious Diseases Society of 
America (IDSA) guidelines recommended universal HCV screening 
in pregnancy which was already suggested by other countries such 
as France and Pakistan a few years earlier.24,48,49 It is, however, not 
being implemented widely thus far as other guidelines, such as from 
the Centers for Disease Control and Prevention and the Society for 
Maternal‐Foetal Medicine, have not yet adopted the recommen‐
dation. It is estimated that such a screening strategy, followed by 
treatment after pregnancy, would be cost‐effective for maternal 
treatment and would identify around 300 newborns with vertical 
HCV in the USA annually.50 However, pregnant women may experi‐
ence psychological stress as treatment start has to be postponed to 
the postpartum period. A recent survey showed that among women 
with (a history of) HCV, 60% were willing to undergo HCV therapy 
during pregnancy given the fact that it would reduce the risk of verti‐
cal transmission, and despite the lack of safety data.51
Despite recent interest and major advancements in available treat‐
ment options, data on DAAs in this population are limited to three ab‐
stracts on either intentional or accidental exposure during pregnancy 
in a small number of women.52‐54 There are a number of important 
aspects to consider prior to implementation of DAA therapy during 
pregnancy, which we review here. These are: (a) The effect of preg‐
nancy on maternal exposure to DAAs; (b) The placental handling of 
DAAs; (c) Safety of DAAs for mother and child during pregnancy; (d) 
Safety of DAAs during the lactation period. Implementation and costs 
of antenatal HCV screening are also important but will not be consid‐
ered here. We identify research gaps on the potential use of DAAs in 
pregnant and breastfeeding women living with HCV.
2  | EFFEC T OF PREGNANCY ON 
MATERNAL E XPOSURE TO DIREC T-AC TING 
ANTIVIR AL S
Pregnancy‐associated anatomical and physiological changes may 
influence drug pharmacokinetics (PK), in some cases leading to the 
need for dose adjustments.55 To date, only one abstract is available 
on sofosbuvir/daclatasvir in pregnancy and two abstracts on sofos‐
buvir/ledipasvir.52‐54 Although all women included in these three 
studies had a rapid HCV RNA response to therapy, no results from 
PK analysis are reported (yet). Because of absence of available clini‐
cal PK data to date, the effect of pregnancy‐induced alterations on 
drug disposition may be predicted based on their PK properties. For 
each DAA, we discuss the impact of pregnancy on maternal DAA 
exposure by considering the potential effect on drug absorption, dis‐
tribution, metabolism and excretion, as well as potential drug‐drug 
interactions (DDIs) with combination antiretroviral therapy (cART) 
for treatment of HIV. The literature search strategy can be found in 
Appendix S1. The expected pregnancy‐induced changes in maternal 
DAA exposure are described below and summarised in Table 1.
2.1 | Absorption
Pregnancy‐induced alterations of gastrointestinal function, such as 
delayed‐gastric emptying, prolonged gastrointestinal transit time 
and reduced gastric acidity, can either increase or decrease drug 
absorption.55,56 Ledipasvir and velpatasvir show pH‐dependent ab‐
sorption, with a decreased solubility at a higher pH. Reduced gastric 
TA B L E  1   Overview safety and pharmacokinetic data of DAAs in pregnancy
DAA combination Genotype
Hypothetical change in maternal exposure 
(mechanism)
Safety concerns based 
on animal data
Priority to be studied in 
clinical trials in pregnancy
SOF/DAC Genotype 1‐4 ↓ DAC exposure (CYP3A4 induction) Yes High
SOF/LDV Genotype 1, 4‐6 ↓ LDV exposure (gastric pH increase) No Moderate
SOF/VEL
SOF/VEL/VOX
Pan‐genotypic ↓ VEL exposure (gastric pH increase)
↓ VEL/VOX exposure
(CYP3A4 induction)
Uncertain High
GZR/ELB Genotype 1,4 ↓ GZR/ ELB exposure (CYP3A4 induction) No Moderate
GLE/PIB Pan‐genotypic ↓ GLE exposure (CYP3A4 induction) Uncertain High
Abbreviations: DAC, daclatasvir; ELB, elbasvir; GLE, glecaprevir; GZR, grazoprevir; LDV, ledipasvir; PIB, pibrentasvir; SOF, sofosbuvir; VEL, vel‐
patasvir; VOX, voxilaprevir.
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acidity during pregnancy may therefore result in lower exposure.57,58 
During pregnancy, women often suffer from nausea and heartburn 
for which antacids and/or proton pump inhibitors (PPIs) may be pre‐
scribed.59 It has been shown that velpatasvir and ledipasvir expo‐
sure in healthy volunteers treated with PPIs such as omeprazole, is 
reduced up to 40%.60,61 Therefore, co‐administration of PPIs with 
velpatasvir or ledipasvir during pregnancy should be avoided if 
possible.57,58
2.2 | Distribution
Apart from physiological changes (eg body volume and tissue per‐
fusion), physicochemical factors (eg drug lipophilicity and molecular 
weight) determine drug distribution. For example, the increase in 
body fat during pregnancy is likely to increase the volume of distri‐
bution of highly lipophilic drugs, such as DAAs, which in turn may 
result in lower peak plasma levels, prolonged half‐life and lower 
amplitude of plasma concentrations at steady state. However, lit‐
tle information is available to estimate the contribution of the in‐
creased fat mass to the decrease in plasma levels often observed 
during pregnancy.55,62 All DAAs, except sofosbuvir, show a high de‐
gree of plasma protein binding.63 Particularly for these highly protein 
bound drugs, an increase in the unbound fraction may be expected 
due to decreased plasma levels of the main drug‐binding plasma pro‐
teins albumin and α1‐acid glycoprotein during pregnancy. For most 
drugs, the total concentration decreases during pregnancy while the 
unbound concentrations are unaffected. Therefore, it is crucial to 
measure the unbound plasma concentration in pregnancy, next to 
total plasma concentrations, to reliably identify the effect of preg‐
nancy on the pharmacologically active unbound concentration. This 
should be taken into account in future studies on DAA pharmacoki‐
netics in pregnancy.64
2.3 | Metabolism
Pregnancy‐induced changes in the activity of drug‐metabolising en‐
zymes including cytochrome P450 (CYP) and the uridine diphosphate 
glucuronosyltransferase (UGT) family have been observed. While 
the mechanism of the observed changes has not been identified, 
accumulated data suggest that the changes are regulated by rising 
concentrations of hormones.55 Increased CYP3A4 capacity in liver 
and/or intestine is expected to have the most profound impact on 
DAA pharmacokinetics compared to other metabolising enzymes.65 
Tracy et al reported that CYP3A activity increased by 35%‐38% dur‐
ing pregnancy66 and, except for sofosbuvir/ledipasvir, exposure to 
all DAA combinations may be affected to some extent by induction 
of CYP3A‐mediated metabolism. The use of potent CYP3A inducers 
in combination with DAAs that are metabolised by CYP3A4 is cur‐
rently contra‐indicated, as this may reduce DAA efficacy, possibly 
resulting in virological failure.65 The moderate pregnancy‐induced 
increase in CYP3A4 activity may have less profound effects com‐
pared to the effects of concomitant use of strong CYP3A inducers 
on DAA exposure, but dose adjustments of DAAs during pregnancy 
may have to be considered. For some DAA combinations, only expo‐
sure to a single component may be affected by pregnancy‐induced 
changes. For example, exposure to velpatasvir and voxilaprevir, 
but not to sofosbuvir, is influenced by CYP3A activity. However, a 
dose adjustment of individual components is complicated since all 
DAA combination treatments are available as fixed‐dose combina‐
tions, except for sofosbuvir and daclatasvir, which are available as 
separate formulations. Data from phase IV trials suggest that sus‐
tained virological response is not related to plasma concentrations 
of glecaprevir in nonpregnant patients on high‐dose proton pump 
inhibitors (PPIs), implying that the levels were well above the thera‐
peutic threshold. A slight decrease in glecaprevir exposure, caused 
by moderate CYP3A4 induction due to pregnancy, is therefore ex‐
pected to be of less clinical relevance.67,68 Regarding daclatasvir, the 
recommended daclatasvir dose of 60 mg QD is increased to 90 mg 
QD when co‐administered with moderate inducers of CYP3A4A, 
as reductions in exposure of 25% have been observed frequently 
for CYP3A4 substrates.62 A moderate increase in CYP3A activity 
due to pregnancy may also require an increase in daclatasvir dose. 
However, the clinical relevance of increased CYP3A4 metabolism for 
daclatasvir in pregnancy is unknown as its oral clearance is signifi‐
cantly lower in women than in men, resulting in higher exposure in 
women.69
2.4 | Excretion
Elimination of DAAs (except for sofosbuvir) occurs mainly via biliary 
excretion as parent drug. Pregnancy may alter the expression of 
drug transporters in metabolising and eliminating organs, but there 
is little quantitative information on the influence of pregnancy on 
transporter activity in the basolateral and canalicular membrane of 
hepatocytes, and the resulting effect on DAA excretion. Due to this 
lack of knowledge, no pregnancy physiologically‐based pharmacoki‐
netic (PBPK) models have been published which simulate the role of 
biliary drug excretion.70 Sofosbuvir is mainly renally eliminated as 
its pharmacologically inactive metabolite GS‐331007 (78%) and to 
a lesser extent as unchanged sofosbuvir (3.5%). Because pregnancy 
leads to an increase in renal blood flow and glomerular filtration rate, 
renal clearance of sofosbuvir may be increased during pregnancy. It 
is, however, unclear whether this could influence plasma levels to 
the point of requiring dose adjustment.55,71
2.5 | Drug‐drug interactions (DDIs) in case of 
maternal viral co‐infection
For the treatment of maternal hepatitis B co‐infection, tenofovir 
disoproxil fumarate (TDF) is preferred.72 As TDF may also be part 
of combination antiretroviral therapy (cART) for treatment of HIV, 
literature on DDIs between cART and DAAs can be consulted.65 
DDIs between HCV and cART are an important consideration in 
the treatment of (pregnant) HCV/HIV co‐infected women,14,15 and 
are well described in the literature.65,73 However pregnancy‐in‐
duced alterations could also influence either HCV and/or HIV drug 
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exposure as a third factor, making the translation of DDIs from the 
nonpregnant patient population to pregnant women complicated. 
Here we do not elaborate on drug combinations that are already 
contra‐indicated in the nonpregnant population, but focus on spe‐
cific DDIs that may be of concern due to the possible effects of 
pregnancy on drug exposure. A first example is efavirenz, com‐
monly used as part of cART, but known to decrease daclatasvir 
exposure via induction of CYP3A4, with an area under the plasma 
concentration‐time curve (AUC) geometric mean ratio (GMR) with 
90% CI of 0.68 (0.60, 0.78).74 The recommended daclatasvir dose is 
therefore increased (90 mg instead of 60 mg once daily) in patients 
using efavirenz. In pregnant women, an increase of daclatasvir 
dose may also be warranted as pregnancy also affects CYP3A4 
activity, resulting in lower daclatasvir plasma levels compared to 
nonpregnant patients. In addition, use of efavirenz with ledipasvir 
results in a reduction of ledipasvir exposure (AUC GMR [90% CI] 
of 0.66 [0.59, 0.75]); the pregnancy‐related increase in gastric pH 
is likely to also decrease ledipasvir exposure.57 Lastly, concomitant 
use of darunavir/ritonavir with sofosbuvir/velpatasvir/voxilaprevir 
results in higher voxilaprevir due to inhibition of organic‐anion‐
transporting polypeptide (OATP)‐1B1, P‐glycoprotein (P‐gp) and 
CYP3A, with an AUC GMR (90% CI) of 2.43 (2.15, 2.75), but is 
considered to be not clinically relevant in the nonpregnant popu‐
lation.75 During pregnancy twice daily darunavir, instead of once 
daily, is recommended and therefore concomitant use of daru‐
navir/ritonavir and sofosbuvir/velpatasvir/voxilaprevir should be 
contra‐indicated.
According to the guidelines, dolutegravir has low potential 
for DDIs and may therefore seem of particular interest for use 
in women living with HCV and HIV.65 However, a recent report 
highlighted an increased incidence of neural tube defects associ‐
ated with dolutegravir use around the time of conception. Further 
safety data are awaited to confirm or refute this finding and in the 
meantime dolutegravir use around the time of conception should 
be avoided,76 although if used after the first trimester, there is no 
increased risk of neural tube defects. As the choice for HCV as 
well as cART is mainly dependent on local drug availability, which 
is limited in low‐income countries, it might not be possible to pre‐
scribe the combination of preference. Based on available data 
regarding possible DDIs between DAAs and cART, and taking po‐
tential effects of pregnancy on their pharmacokinetics into con‐
sideration, the choice of combination treatment should be made 
by local physicians.
3  | PL ACENTAL HANDLING OF DIREC T-
AC TING ANTIVIR AL S
Drug transport across the placental barrier is a major determinant 
of foetal exposure and toxicity. However, for some conditions foetal 
exposure to maternally administered drugs could potentially provide 
pre‐exposure prophylaxis and thereby reduce the chance of vertical 
transmission, as has been hypothesised for HIV.77
3.1 | Placental handling in human pregnancy
For ethical reasons, pregnant women have historically often been 
excluded from clinical trials in the drug development process, result‐
ing in a gap of knowledge regarding both maternal and foetal drug 
exposure throughout gestation. However, recent reports on the im‐
portance of conducting pharmacological research in pregnancy and 
possible research strategies highlight that times are changing.78,79 
To our knowledge, information on DAA exposure during pregnancy 
is currently limited to three conference abstracts. However, none 
of these studies collected data on foetal exposure (eg as umbilical 
cord blood concentrations) as treatment was either discontinued or 
completed during pregnancy and it is therefore not known whether 
or how well these DAAs cross the human placental barrier in vivo.
3.2 | Placental handling in pre‐clinical research
Studies on placental handling of DAAs are solely based on devel‐
opmental toxicology studies in animal models. As shown in Table 2, 
placental transfer of sofosbuvir, daclatasvir, glecaprevir, pibrentas‐
vir, grazoprevir and elbasvir has been observed in rats. Placental 
transfer of grazoprevir and elbasvir has, in addition to rats, also been 
observed in rabbits, but to a minimal extent. However, because of 
interspecies differences in placental anatomy, placental transfer 
data from animal studies is of poor translational value. Compared 
to the placenta of rabbit, rat and mouse, the structure of the human 
placenta differs in gross shape, histology of the maternofoetal inter‐
face and type of maternofoetal interdigitation, which may all affect 
placental drug transfer.80
3.3 | Prediction of placental drug handling ex vivo
To predict transfer of drugs across the human placenta in vivo, data 
from animal studies may be combined with information on drug‐
specific physicochemical characteristics. Comparing DAAs based 
on their specific physicochemical properties provides information 
on potential changes in their pharmacokinetics during pregnancy 
(Chapter 2) and a similar approach can yield estimates of placental 
transfer, and hence provides a rough estimate of foetal exposure. A 
review by Giaginis et al summarised the factors affecting transport 
of drugs across the placental barrier.81 In general, maternofoetal 
exchange increases with gestational age because of physiological 
changes, eg reduced membrane thickness and increased uterine 
blood flow, inherent to the increased foetal demand of oxygen and 
nutrients.80 Passive diffusion is the major route of placental transport 
and is responsible for rapid transfer of lipophilic drugs with a mo‐
lecular weight of <500 Da. Larger molecules may also be subjected 
to passive diffusion, which is a relatively slow process 81; all DAAs 
are highly lipophilic, indicated by a log P >2.5 (except for sofosbu‐
vir, log P = 1.62), favouring effective passive diffusion. On the other 
hand, their high molecular weight (all >500 Da) may hamper or at 
least slow the process. In addition, the degree of ionisation and pro‐
tein binding also influence the rate and extent of placental transfer. 
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Protein binding will contribute to trapping of drug in the foetal or 
maternal circulation, and as maternal and foetal plasma protein con‐
centrations differ and change with advancing gestational age, the 
maternal‐to‐foetal ratio of total drug plasma concentration may vary 
accordingly.82 Next to passive diffusion, drug transport across the 
placental barrier may also be carrier‐mediated, either as facilitated 
diffusion or via active transporters. All DAAs included in this re‐
view are ATP‐binding cassette (ABC) transporter substrates of P‐gp 
(ABCB1) and/or Breast Cancer Resistance Protein (BCRP/ABCG2). 
As these efflux transporters are expressed at the apical side of the 
syncytiotrophoblast layer, they possibly play a role in reducing foetal 
exposure. Xenobiotics interacting with these transporters may also 
influence placental transfer of DAAs.83 Since placental transporter 
expression changes during pregnancy, placental transfer may be also 
dependent on timing of treatment during pregnancy. A reduction in 
P‐gp mRNA and protein levels from first trimester towards term has 
been reported, likely related to the general decrease in foetal pro‐
tection after the critical period of organogenesis. Therefore, there 
is a greater potential of P‐gp substrates (eg most DAAs), to reach 
the unborn child with advancing gestational age. Literature on BCRP 
expression throughout gestation is inconsistent.84
As outlined above, different factors either facilitate or impede 
drug transport across the placental barrier. Hence, it is difficult to 
estimate the extent of placental transport of a specific drug at a spe‐
cific time point during pregnancy. In addition to in vitro techniques 
using immortalised cell lines or tissue explants, computer‐assisted 
modelling attempts are useful to explore the contribution of the 
physicochemical properties to placental transport.85,86 The dual 
side placental perfusion model has proven to be a valid experimen‐
tal method to study the transport of xenobiotics ex vivo and is cur‐
rently used extensively to investigate placental passage.87 As stated 
before, it is hypothesised that the extent of placental drug transfer 
TA B L E  2   Safety data from reproductive teratogenicity studies of DAAs in pregnancy
DAA therapy Prenatal and postnatal development Placental transfer Lactation
DAA 
combination Drug
Safety 
concerns?
Tested animal species  
(Dose and duration)
Transfer 
across 
placenta
Tested animal species 
(% of maternal plasma 
levels)
Transfer into milka 
(% of maternal 
plasma levels)
SOF/DAC SOFb No Rats: 10x RHD, GD6‐18, GD6‐LD20
Rabbits: 28x RHD, GD6‐19
Yes Rats Yes (80%)
DAC Yesc Rats: 4x RHD, GD7‐19
Rabbits: 16x RHD, GD6‐15
Yes Rats Yes (170%‐200%)
SOF/LDV SOFb No Rats: 10x RHD, GD6‐18, GD6‐LD20
Rabbits: 28x RHD, GD6‐19
Yes Rats Yes (80%)
LDV Possiblec Rats: 4x RHD, GD6‐18
Rabbits: 2x RHD, GD7‐20
Unknown Not tested Yes
SOF/VEL 
SOF/VEL/VOX
SOFb No Rats: 10x RHD, GD6‐18, GD6‐LD20
Rabbits: 28x RHD, GD6‐19
Yes Rats Yes (80%)
VEL Possibled Rats: 6x RHD, GD6‐17, GD6‐LD20
Rabbits: 0.5‐0.7x RHD, GD7‐20
Mice: 31x RHD, GD6‐15
Not evident Rats Yes (173%)
VOX No Rats: 141x RDH, GD6‐LD20
Rabbits: 4x RHD, GD7‐19
Unknown Not tested Yes
GZR/ELB GZR No Rats: 117x RHD, GD6‐20, GD6‐LD20
Rabbits: 41x RHD, GD7‐20
Yes Rats (89%)
Rabbits (7%)
Yes (400%)
ELB No Rats: 10x RHD, GD6‐20, GD6‐LD20
Rabbits: 18x RHD, GD7‐20
Yes Rabbits (0.8%)
Rats (2.2%)
Yes (87%)
GLE/PIB GLE Possiblee Rats: 53x RHD, GD6‐18, GD6‐LD20
Rabbits: 0.07x RHD, GD7‐19
Yes Rats Yes (<8%)
PIB No Rabbits: 1.5x RHD GD7‐19
Mice: 51x RHD GD6‐15, GD6‐LD20
Yes Mice Yes (150%)
Abbreviations: DAC, daclatasvir; ELB, elbasvir; GD, gestation day; GLE, glecaprevir; GZR, grazoprevir; LD, lactation day; LDV, ledipasvir; PIB, pibren‐
tasvir; RHD, recommended human dose; SOF, sofosbuvir; VEL, velpatasvir; VOX, voxilaprevir.
aTransfer into milk was studied in rats. 
bExposure to predominant circulating metabolite of sofosbuvir (GS‐331007). 
cAt a high dose (4.6‐fold RHD), an increased incidence of skeletal variations (vertebrae, sternea, ribs) in rats was observed. These effects are likely 
related to a decrease in maternal body weight gain and decreased food intake. 
dA possible teratogenic effect was indicated in rabbits where an increase in total visceral malformations was seen in exposed animals at AUC expo‐
sures up to 0.7‐fold RHD for SOF/VEL and 0.5‐fold RHD for SOF/VEL/VOX. 
eMaternal toxicity with some embryofoetal toxicity precluded the ability to evaluate glecaprevir in the rabbit at human clinical exposures. 
744  |     FRERIKSEN Et al.
increases towards term.80 Therefore, data from ex vivo placental 
perfusion experiments using term placentas potentially overesti‐
mate foetal exposure during earlier phases of pregnancy.87 For a va‐
riety of drugs studied, transfer across term placentas ex vivo shows 
good correlations with in vivo maternal and cord blood concentra‐
tion. Hence, data from ex vivo placental perfusion experiments may 
also be used to rank the various DAAs with regard to their potential 
to cross the placenta.88
4  | SAFET Y OF DIREC T-AC TING 
ANTIVIR AL S DURING PREGNANCY
In the absence of conclusive evidence from DAA exposure during 
human pregnancy, assessments of DAA safety are based on data 
derived from animal reproduction toxicology studies. Table 2 sum‐
marises the results of these pre‐clinical studies on embryofoetal 
toxicity, teratogenicity, placenta transfer and breast milk. The lit‐
erature search strategy can be found in Appendix S1. Although the 
majority of the adverse effects of drugs are related to direct foetal 
exposure because of placental transfer, drugs may also affect the 
developing foetus indirectly by disturbing placental function.89 
However, the species‐specific placental physiology, as well as im‐
munological and endocrinological differences hamper the transla‐
tion of placental drug effects from animal studies.90 A large registry 
of infants intrauterine‐exposed to DAAs is needed to assess long‐
term effects in humans. Such an approach has been undertaken for 
HIV, the Antiretroviral Pregnancy Registry, and has been proven 
to be successful in monitoring effects of intrauterine exposure to 
 antiretrovirals.91 Adding HCV to an existing pregnancy registry may 
be an option worth considering.
4.1 | Sofosbuvir/daclatasvir
The only data available on sofosbuvir/daclatasvir in human preg‐
nancy include one study on accidental sofosbuvir/daclatasvir ex‐
posure around the time of conception (n = 7). No adverse birth 
outcomes were reported but one infant tested HCV positive at 
18 months with low viral load, which is not unexpected as all women 
discontinued therapy early, before week 9 of gestation.53
Sofosbuvir administration showed no adverse effects in pre‐
clinical reproduction toxicology studies using rabbits at exposure 
levels comparable to 10‐fold the recommended human dose (RHD). 
As sofosbuvir could not be detected in rodent plasma probably due 
to high esterase activity, assessment of reproductive toxicity tests 
in rats are based on exposure to the major (inactive) metabolite 
GS‐331007. At GS‐331007 exposure levels following a 10‐fold RHD, 
no effect on intrauterine development or any malformations were 
seen in rats.92,93 As sofosbuvir was detectable in human plasma, 
data from rodent studies regarding sofosbuvir exposure should 
be interpreted with caution. For daclatasvir, embryofoetal toxicity 
(external and/or visceral malformations) in rabbits and rats was re‐
ported by the EMA. However, exposure in rats and rabbits was 4.6 
and 16‐fold RHD respectively.94 Remarkably, the Food and Drug 
Administration (FDA) reported no concerns for embryofoetal toxic‐
ity in rats when exposed to 6x RHD and in rabbits when exposed to 
22‐fold RHD.95
In the general patient population, this DAA combination has a 
favourable safety profile. The most frequently reported adverse re‐
actions were fatigue, headache and nausea.71,74 A special warning 
for the use of sofosbuvir (in combination with either daclatasvir or 
ledipasvir) and amiodarone was based on observed bradycardia in 
several patients.96
4.2 | Sofosbuvir/ledipasvir
Data on sofosbuvir/ledipasvir use during pregnancy are limited to 
two conference abstracts: one study performed in India included 
pregnant women living with HCV who requested treatment be‐
cause of anxiety about vertical transmission (n = 15), and DAAs 
were started during the second and early third trimester54; and the 
other, previously mentioned, is a phase I trial of sofosbuvir/ledipasvir 
started during the second trimester of pregnancy (n = 8) from the 
USA.52 Both studies reported no safety concerns; there were are no 
cases of vertical transmission to date in the USA study, but the num‐
ber is yet to be reported for the Indian study. Considering the small 
number of women in the two studies, a lack of vertical transmission 
would not be unusual even in the absence of treatment.
The decision to study sofosbuvir/ledipasvir in a clinical setting is 
supported by a favourable embryofoetal safety profile based on pre‐
clinical studies. As stated earlier in this review, sofosbuvir use seems 
safe for the developing offspring in rats and rabbits. At exposure 
levels of 3.4‐fold RHD, minor effects of ledipasvir on fertility of fe‐
male rats were reported. However, this was not seen at 2‐fold RHD 
and effects were likely related to non‐adverse maternal toxicity.97 
The FDA reported that there are no clear adverse effects on foetal 
development in rats and rabbits at 4‐fold and 2.3‐fold RHD respec‐
tively. However, a lower body weight of the offspring in rats at an 
exposure level of 4‐fold RHD is reported by the EMA and at slightly 
higher exposure levels (4.6‐fold RHD), an increased incidence of 
skeletal variations was observed.57,98 In the absence of other toxicity 
findings, this effect on the offspring may be related to non‐adverse 
maternal toxicity.
In terms of adverse events, fatigue and headache were reported 
in adult patients treated with ledipasvir/sofosbuvir.57
4.3 | Sofosbuvir/velpatasvir (±voxilaprevir)
The EMA reports a possible teratogenic effect (visceral malforma‐
tions) due to velpatasvir exposure of 0.7‐fold RHD in pregnant rab‐
bits; however, according to the FDA label, this is written as being of 
“no significant effect”. Mice and rat studies found no embryofoetal 
adverse effects at 23‐fold RHD and 4‐fold RHD respectively. There 
was no evidence of placental transfer of velpatasvir as it could not 
be detected in litter after a single dose of 30 mg/kg on gestation 
day 13 or 18. Maternal voxilaprevir administration did not result in 
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adverse embryofoetal effects in rats (141‐fold RHD) and rabbits (4‐
fold RHD). No data on placental transfer of voxilaprevir in animals 
have been reported.99‐102
The most common adverse effects seen in clinical studies were 
headache, fatigue and nausea. When combined with voxilapre‐
vir, diarrhoea and nausea were also reported as common adverse 
events.58,75
4.4 | Grazoprevir/elbasvir
Grazoprevir and elbasvir reproduction studies have failed to re‐
veal any adverse effects in rats (10‐fold RHD) and rabbits (18‐fold 
RHD).103,104
In patients with HCV, reported adverse reactions were fatigue and 
headache with a special warning for plasma liver enzyme (ALT) eleva‐
tions. The rate of late ALT elevations during treatment was directly 
related to plasma exposure to grazoprevir and generally occurred from 
approximately 8 weeks after start of treatment. These late ALT eleva‐
tions were typically asymptomatic and resolved with ongoing therapy 
with grazoprevir/elbasvir or after completion of therapy.105
4.5 | Glecaprevir/pibrentasvir
Registration files state that either glecaprevir administration in rats 
(63‐fold RHD) or pibrentasvir administration in mice (100‐fold RHD) 
did not result in reproductive toxic effects. However, this conclusion 
was considered questionable because maternal toxicity with some 
embryofoetal toxicity precluded the ability to evaluate glecaprevir 
in rabbits at human clinical exposures.106,107
In clinical studies, the most commonly reported adverse reac‐
tions were fatigue and headache. Occasionally, elevations of total 
bilirubin levels have been reported in patients using glecaprevir/pi‐
brentasvir. The effect is more pronounced with higher glecaprevir 
plasma levels and is likely due to glecaprevir‐mediated inhibition of 
bilirubin transport and metabolism.108 Although maternal bilirubin 
elevations are asymptomatic and transient, the effects on the foetus 
may be questionable as unconjugated bilirubin can cross the placen‐
tal barrier.109 Therefore, it may be hypothesised that high maternal 
bilirubin levels may increase the risk of neonatal jaundice.
5  | SAFET Y OF DIREC T-AC TING 
ANTIVIR AL S DURING THE L AC TATION
As studies have shown that avoidance of breastfeeding does not 
seem to reduce the chance of vertical HCV transmission, breast‐
feeding is considered safe among women with chronic HCV, except 
for women with cracked nipples.110 Since breastfeeding is currently 
not contra‐indicated in these patients living with HCV, it is important 
to gather information of the potential use and safety of DAAs during 
the lactation period.
To evaluate safety of drug use during the lactation period the 
following aspects should be considered: the effect of drugs on milk 
production; drug concentrations in milk; and the effects of exposure 
on the breastfed child. In the absence of human data, data on DAA 
exposure in milk are limited to rat studies. They should be interpreted 
with caution due to species‐specific differences in lactation physiol‐
ogy such as mammary gland anatomy, storage and release of milk into 
ducts, protein and fat composition of milk and the expression of drug 
transporters in mammary tissue, as these factors play a major role in 
the extent passage of drugs into milk.111 Data obtained from rat studies 
showed that DAAs are transferred into milk, but no effects on growth 
and development were observed in nursing pups exposed to DAAs via 
milk.97,99,104,107 Maternal plasma‐to‐milk ratios have been reported to 
differ considerably between DAAs in rat studies. Whereas glecaprevir 
concentrations in milk are <8% of maternal plasma levels, grazoprevir 
milk concentrations exceed maternal plasma concentrations (400%). 
This disparity in extent of milk transfer is, however, difficult to explain 
based on the physicochemical differences and transporter profiles of 
the two compounds.112 Grazoprevir and glecaprevir have a compara‐
ble molecular weight with a similar degree of plasma protein binding. 
Moreover, glecaprevir is known to be a BCRP substrate, whereas gra‐
zoprevir is not. As this transporter is considered to contribute to ex‐
cretion of drugs into milk,113 the proportion of glecaprevir transferred 
to milk is expected to be high, but extensive plasma protein binding 
impedes its transfer into breastmilk.
6  | DISCUSSION
There are multiple reasons to either consider or defer DAA treat‐
ment during pregnancy as reviewed extensively by others.7,114,115 
Although the AASLD/IDSA guidelines recommend universal screen‐
ing of pregnant women,24 no DAA regimen is currently approved for 
treatment during pregnancy because of insufficient human safety 
and efficacy data and treatment is therefore delayed until after de‐
livery. The high chance of loss to follow‐up of both mother and her 
HCV‐exposed child in many settings, together with loss of health‐
care insurance after pregnancy may complicate adequate maternal 
and paediatric treatment, highlighting the pregnancy period as a 
unique window of opportunity to both cure the mother and prevent 
vertical transmission of HCV.46,116
Standard dosing regimens of currently used DAAs may be sub‐
optimal for the pregnant patient population as pregnancy‐induced 
pharmacokinetic changes may influence maternal drug exposure, 
hence efficacy of the drugs. The expected increased elimination of 
DAAs, both because of a potentially increased biliary excretion as 
well as induction of metabolising enzymes, may potentially lead to 
subtherapeutic levels. This pregnancy‐induced effect is expected to 
be less pronounced for sofosbuvir/ledipasvir and glecaprevir/pibren‐
tasvir compared to other DAA combinations. Instead of adjusting the 
dose—which is rarely done in clinical practice—a DAA combination 
less prone to pregnancy‐induced effects could be chosen, if available.
Apart from data on maternal exposure to DAAs, early data on 
placental handling and subsequent foetal exposure are important to 
study possible placental toxicity of DAAs as well as the potential of 
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DAAs to provide foetal pre‐exposure prophylaxis. Several ex vivo 
and in vitro models may provide insight into pharmacokinetics, in‐
cluding placental transfer of drugs.87,117 The ex vivo placental perfu‐
sion model, using human term placentas yet unexposed to drugs, can 
be helpful in studying the initial phase of placental DAA handling and 
may provide an estimation of foetal exposure. Subsequently, preg‐
nancy‐PBPK modelling can be used as a tool to assess foetal plasma 
levels upon maternal administration of different dosing regimens.118 
In the view of potential pre‐exposure prophylaxis, foetal exposure to 
DAAs may, next to maternal viral load reduction, contribute to the 
reduced risk of vertical transmission. In contrast to HIV, research has 
yet not focused on the use of DAAs for pre‐exposure prophylaxis in 
the general population. Future research is needed to clarify the role 
of foetal exposure in reducing the chance of vertical transmission.
Most DAAs are reported to cross the placental barrier in either 
rats and/or rabbits when administered early during pregnancy. In 
clinical practice, it is more likely that treatment will be started late 
in pregnancy to avoid the critical period of foetal organogenesis. 
Therefore, data from animal reproductive toxicity studies are difficult 
to extrapolate to the human clinical situation as there is a difference 
in timing of treatment and because of the large interspecies variabil‐
ity in placental anatomy, both affecting the extent of placental pas‐
sage. Based on animal studies, it is likely that postpartum exposure 
to DAAs may occur via breastfeeding. Nowadays, breastfeeding is 
not contra‐indicated in women with chronic HCV. However, this ad‐
vice may change if breastfeeding women are treated with DAAs in 
the future, given that fact that all DAAs are detected in milk of rats, 
with grazoprevir levels in milk being 400% of maternal levels.
In order to decide on the timing of treatment, it is not only im‐
portant to assess the most critical window of possible teratogenic 
effects of drug exposure (generally the earlier phase of pregnancy), 
but also to consider the timing of vertical transmission of HCV. As 
peripartum blood‐blood contact may be the most important source 
of vertical transmission, maternal HCV RNA should be undetectable 
during delivery. Ideally, treatment would be completed before de‐
livery. In that case, taking into account that women living with HCV 
may deliver preterm,40 the optimal time period to start DAA treat‐
ment may be at the end of the second trimester (at around week 
23/24 of gestation) or early third trimester (at around 27/28 weeks 
of gestation), in case of a 12‐ or 8 week treatment period respec‐
tively, and may have to be extended until after delivery to complete 
treatment. For late presenters (>28 weeks of gestation), treatment 
may still be effective as DAAs cause a rapid viral decline, resulting in 
undetectable HCV RNA in just 2‐4 weeks.119
The choice for a specific DAA combination should be based on 
safety data from animal reproductive studies and safety and efficacy 
data from the nonpregnant patient population. Further research on 
safety, PK and efficacy in pregnant women is warranted prior to im‐
plementation of treatment in this population. Research on the po‐
tential effect of maternal DAA use on the state of foetal‐directed 
immune tolerance is of particular importance in this population as 
DAAs are thought to improve the proliferative potential of HCV‐spe‐
cific T cell response again which may decrease immune tolerance.120 
Furthermore, foetal exposure should be assessed, eg by measuring 
umbilical cord blood concentrations, when women continue treat‐
ment until after delivery. This information is needed to assess the 
potential of DAAs for pre‐exposure prophylaxis. Furthermore, an 
international registry is needed to provide a safety net to detect ad‐
verse effects after intrauterine or postpartum DAA exposure.
Next to safety and efficacy data, various other factors have to be 
taken into account to decide which HCV treatment regimen should 
be preferred. Firstly, genotype specificity of DAAs plays an import‐
ant role as the phase I study on sofosbuvir/ledipasvir in pregnancy 
had to exclude a third of the pregnant women for participation be‐
cause of genotype 2 or 3 infection.52 As genotyping is costly, not 
feasible in all settings and delays treatment start, future research 
may focus particularly on the use of the pan‐genotypic DAA com‐
binations glecaprevir/pibrentasvir and sofosbuvir/velpatasvir (with 
or without voxilaprevir) during pregnancy. Furthermore, the use 
of co‐medication may determine the DAA regimen of first choice. 
In the case of HCV/HIV co‐infection, EFV should not be used in 
combination with any DAA and when boosted PIs are part of cART, 
only sofosbuvir/ledipasvir or sofosbuvir/velpatasvir should be used 
concomitantly. If women use proton pump inhibitors (PPIs) during 
pregnancy, neither sofosbuvir/ledipasvir nor sofosbuvir/velpatasvir 
should be prescribed. In case of concomitant use of strong CYP3A4 
inducers, eg rifampicin, sofosbuvir/ledipasvir should be advised. 
Lastly, local drug availability and costs may determine which drug 
will be prescribed, despite the fact that this DAA regimen may not 
be the regimen of first choice based on animal safety data, genotype 
specificity or potential for DDIs. An important example that needs 
to be taken into consideration is the widespread use of sofosbuvir/
daclatasvir in Egypt, which is one of the countries with the highest 
HCV prevalence worldwide.121 Women becoming pregnant using 
daclatasvir are advised to stop their treatment because of the lack 
of knowledge regarding safety and efficacy,53 despite not knowing 
whether cessation of treatment during pregnancy, likely resulting 
in HCV disease relapse, may be less advantageous than continuing 
treatment. Given the paucity of data and the potential exposure to 
daclatasvir during conception or early pregnancy, research is needed 
on daclatasvir efficacy in human pregnancy and global pregnancy 
registry databases are warranted to assess its safety.
Ideally, a pan‐genotypic, safe and effective DAA combination 
would be available to all pregnant women living with HCV, diagnosed 
by a (cost‐effective) universal screening programme. However, cost‐
effectiveness of specific DAA combinations, local drug availability 
and preferences of pregnant women themselves and their treating 
physicians play a dominant role and these factors have to be taken 
into consideration.
7  | CONCLUSION
Treatment of HCV with DAAs during pregnancy and breastfeed‐
ing is not currently recommended because of lack of data on safety, 
leaving pregnant women diagnosed with HCV untreated until after 
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delivery (which in itself maybe distressing for the mother and deter 
her from breastfeeding). In our opinion, this window of opportunity 
to simultaneously improve maternal health and prevent vertical 
transmission should not be missed. There is an urgent need to study 
DAAs in pregnant and breastfeeding women to target these patient 
populations as well as their HCV‐exposed children and to contribute 
to the HCV elimination goal of 2030.
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